For example, bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, in combination with standard chemotherapy, improves survival in non-squamous histology, but is contraindicated in patients with squamous cell carcinoma [29, 30]. The gene discussed is VEGFA; the disease is squamous cell carcinoma.